ライフサイエンスコーパス: confidence limit

1 rom about 6.4 degrees C to 14 degrees C (90% confidence limits).

2 4 degrees C from 1981-2000 to 2091-2100 (90% confidence limits).

3 e-dependent changes in expression at the 99% confidence limit.

4 onent was dependent on cell cycle at the 99% confidence limit.

5 did not change significantly within the 95% confidence limit.

6 e interactions were resolved with acceptable confidence limits.

7 l sensitivity losses exceeded the normal 95% confidence limits.

8 individual macrobeads and by using binomial confidence limits.

9 tivity and specificity for each test and 95% confidence limits.

10 p < 0.001), with minimal bias and narrow 95% confidence limits.

11 of APOE genotypes to be assessed with useful confidence limits.

12 heir precision, usually given in the form of confidence limits.

13 antile regression showed modestly smaller MD confidence limits.

14 7% vs 5%, p=0.75, OR estimate 1.44, 95% Wald confidence limits 0.23-7.85).

15 e interrater reliability was 0.45 (upper 95% confidence limit = 0.58).

16 ty by the same assessors was 0.54 (upper 95% confidence limit = 0.77); the interrater reliability was

17 42 (23.6%) did not (kappa = 0.828; lower 95% confidence limit = 0.790).

18 demonstrated excellent (r = 0.956, lower 90% confidence limit = 0.948; kappa = 0.73, 95% confidence i

19 nt encounters was high (r = 0.964, lower 90% confidence limit = 0.950; kappa = 0.80, 95% confidence i

20 association between PFS and OS was 0.30 (95% confidence limits = 0.26, 0.32).

21 sfusion (p = 0.06, relative risk = 1.90, 95% confidence limits = 0.95-3.78).

22 HCoV infection than with LDI (OR, 0.27 [95% confidence limit, 0.13-0.58]).

23 .10), and increased lactate (0.6 mmol/L [95% confidence limit, 0.3, 0.8]; p(group) < 0.0001) compared

24 of within-couple HIV transmission (upper 95% confidence limit, 0.30/100 couple-years of follow-up).

25 when compared with the third trimester (95% confidence limits, 0.36 to 2.81) (both P < 0.001).

26 sted long-term survival (hazard ratio, 0.64; confidence limits, 0.50 to 0.83; P=0.0005).

27 The hazard ratio for death was 0.72 (confidence limits, 0.51 to 1.01) in the conservative str

28 sk reduction of 33% (hazard ratio, 0.67; 95% confidence limits, 0.55, 0.81; P<0.0001), whereas those

29 ays was 88%, with a kappa value of 0.75 (95% confidence limits, 0.73 to 0.76).

30 higher HDLc showed no benefit (RR, 1.06; 95% confidence limits, 0.88, 1.27; P=0.53).

31 ival hazard ratio of 0.98 per unit increase (confidence limits, 0.97 to 0.98; P<0.0001).

32 d a free energy of 8.3 kcal/mol with tighter confidence limits, +0.5/-0.8 kcal/mol.

33 physician and patient was poor at 0.14 (95% confidence limit, -0.01 to 0.30) for simple kappa and 0.

34 sal pH (mean difference, 0.015 pH units; 95% confidence limits, -0.054, 0.084).

35 imits, -0.68, 1.79) and -0.018 pH units (95% confidence limits, -0.069, 0.032) for "fresh" red cells

36 limits, -0.6, 1.64) and -0.033 pH units (95% confidence limits, -0.080, 0.129) for "stored" red cells

37 032) for "fresh" red cells and 0.52 kPa (95% confidence limits, -0.6, 1.64) and -0.033 pH units (95%

38 amucosal pH, respectively, was 0.56 kPa (95% confidence limits, -0.68, 1.79) and -0.018 pH units (95%

39 dose (SYNERGY, difference -0.06, upper 95.2% confidence limit: 0.02, p for noninferiority <0.001; SYN

40 RGY half dose, difference -0.03, upper 95.2% confidence limit: 0.05, p for noninferiority <0.001).

41 by the 2.5-fold wider confidence limits (95% confidence limits: 0.06, 0.43).

42 prior 2 years with no therapy was 0.36 (95% confidence limits: 0.21, 0.61).

43 e anemia (hemoglobin < 70 g/L) was 0.77 (95% confidence limits: 0.39, 1.51) in the twice-yearly dewor

44 patency of ITA grafts (odds ratio: 0.63; 95% confidence limits: 0.43 to 0.91; p = 0.013), but late pa

45 ed with DSA production (risk ratio 0.92 [95% confidence limits: 0.85, 0.99], and 0.70 [0.49, 1.00]).

46 e mix-adjusted death risk ratio of 0.90 (95% confidence limits: 0.86, 0.95; P < 0.001), whereas those

47 otene supplements with placebo was 1.10 (95% confidence limits: 0.89, 1.36; P = 0.39).

48 ty COMT diplotypes (hazard ratio = 1.42; 95% confidence limits: 0.96, 2.09).

49 % confidence limits 1.3 to 2.6) and 1.4 (95% confidence limits 1.0 to 2.0), respectively.

50 e lethal alleles per individual are 1.9 (95% confidence limits 1.3 to 2.6) and 1.4 (95% confidence li

51 using the F-wave (regression slope 2.33, 95% confidence limits 1.30-3.36).

52 combined, the responder rate was 12.5% (90% confidence limit, 1% to 43%) with placebo, compared to 4

53 week rotations was 0.97 (1-sided 97.5% upper confidence limit, 1.07; noninferiority P = .007).

54 hs (relative risk, 0.98; 95% one-sided upper confidence limit, 1.13; P<0.001 for noninferiority).

55 dities, and symptom (hazard ratio, 1.34; 95% confidence limit, 1.17-1.53; P<0.001).

56 ys (relative risk, 1.00; 95% one-sided upper confidence limit, 1.22; P<0.001 for noninferiority) and

57 ds ratio for mortality increased by 2.2 (95% confidence limits, 1.8, 2.7).

58 Pg-Paco2 gap (mean difference, 0.03 kPa; 95% confidence limits, -1.66, 1.72) or gastric intramucosal

59 ty COMT diplotypes (hazard ratio = 2.35; 95% confidence limits: 1.66, 3.32), an effect not found in s

60 difference from control 11.0%; two-sided 90% confidence limit, -11.0% to 32.9%; P=0.01 for noninferio

61 difference, 3.7 percentage points; 95% upper confidence limit, 12.56 percentage points; P=0.01 for no

62 Fourteen patients (23%; 95% lower confidence limit, 13%) achieved major cytogenetic respon

63 ; hazard ratio for PCI versus CABG=1.68, 95% confidence limits, 138-2.04; P<0.001).

64 ry for the city equal to 29 Gg/yr (5% to 95% confidence limits, 15 to 54 Gg/yr).

65 h conversion had low sensitivity (27.3% [95% confidence limit 16.6-41.4]) and high specificity (89.8%

66 alence declined from 18.9% in 1957-1958 (95% confidence limits: 18.4%, 19.4%) to 4.9% in 2009-2012 (9

67 etween 10 mg CCX140-B and placebo (upper 95% confidence limit 2%; p=0.08).

68 vs 2%, p=0.003, OR estimate 10.32, 95% Wald confidence limits 2.04-102.46).

69 ed to a 4.7-fold increased risk for HCC (95% confidence limits = 2.2, 9.4).

70 uring the 2 yr of the study (exact 95% upper confidence limit, 2.2).

71 The study estimated that 3.34 million (95% confidence limit, 2.39-4.15 million) life-years were gai

72 ars of age had an annual risk of death of 4 (confidence limit, 2.8-5.4) times that of normal contempo

73 y thrombosis occurred in 3 patients (4%; 70% confidence limits, 2% to 7%).

74 py (hazard ratio for noncompliance=2.79; 95% confidence limits, 2.19-3.54; P<0.001; hazard ratio for

75 of overall survival (hazard ratio, 4.9; 95% confidence limits, 2.2-10.8; P < .001).

76 ilar mean arterial pressure (-1.1 mm Hg [95% confidence limit, -2.3, 0.2]; p(group) = 0.10), and incr

77 resulted in a naive rate ratio of 3.62 (95% confidence limits: 2.67, 4.92).

78 to 43%) with placebo, compared to 40.0% (90% confidence limit, 22% to 61%) with QAX576.

79 negative predictive value, 57% (eight of 14; confidence limits = .29, .82).

80 There were 5 hospital deaths (6%; 70% confidence limits, 3% to 10%).

81 The major response rate was 13% (95% confidence limits, 3% to 32%) for IWF A to C and 16% (95

82 strumental-variable rate ratio was 5.02 (95% confidence limits: 3.45, 7.31), 39% higher than the naiv

83 = .72, .95); specificity, 73% (eight of 11; confidence limits = .39, .94); positive predictive value

84 d with a 9.4-fold elevation in HCC risk (95% confidence limits = 4.7, 18.7).

85 d with a 12.6-fold increase in HCC risk (95% confidence limits = 4.7, 33.6).

86 fference, 0.7 percentage points; upper 97.5% confidence limit, 4.0 percentage points; P=0.02 for noni

87 difference from control 16.4%; two-sided 90% confidence limit, -4.3% to 37.1%; P=0.002 for noninferio

88 its: 18.4%, 19.4%) to 4.9% in 2009-2012 (95% confidence limits: 4.0%, 5.8%).

89 mg CCX140-B and placebo (one-sided upper 95% confidence limit -5%; p=0.01) and a -10% difference betw

90 patients with CTDs (relative risk, 8.1; 95% confidence limit, 5.1-12.9; chi(2)1 = 112.0; P < 10(-3))

91 mits, 3% to 32%) for IWF A to C and 16% (95% confidence limits, 5% to 34%) for IWF D to H; response d

92 .0, -16.4 g), and atenolol (mean, -28.1; 95% confidence limits, -50.9, -5.3 g).

93 Amiodarone reduced total mortality by 19% (confidence limits, 6% to 31%; P<.01), with somewhat grea

94 -65.5, -20.2 g), captopril (mean, -38.7; 95% confidence limits, -61.0, -16.4 g), and atenolol (mean,

95 approximately 1000-fold higher in first (95% confidence limits, 611 to 1376) and second (95% confiden

96 rotective efficacy, 93%; lower one-sided 95% confidence limit, 62%).

97 fidence limits, 611 to 1376) and second (95% confidence limits, 633 to 1623) trimester biopsies when

98 was achieved in 48 patients (77%; 95% lower confidence limit, 65%); median response duration was 9.1

99 d with hydrochlorothiazide (mean, -42.9; 95% confidence limits, -65.5, -20.2 g), captopril (mean, -38

100 Sensitivity was 86% (37 of 43; 95% confidence limits = .72, .95); specificity, 73% (eight o

101 otective efficacy, 100%; lower one-sided 95% confidence limit, 75%).

102 ile with lower heart rate (-7.0 min(-1) [95% confidence limit, -8.7, -5.1]; p(group) < 0.0001), simil

103 e plasma estradiol level was 4.3% lower (95% confidence limits, -8.3%, -0.2%) for a substitution of 5

104 ); positive predictive value, 92% (37 of 40; confidence limits = .80, .98); and negative predictive v

105 informative cases analyzed (P=2.4x10-7; 95% confidence limits 87%-100%).

106 expected (O/E) ratios and corresponding 95% confidence limits (95% CL) of cigarette smoking were 0.7

107 h ERCC1 C8092A [hazard ratio (HR), 0.72; 95% confidence limits (95% CL), 0.60-0.86; P = 0.0004] and G

108 e of precision as seen by the 2.5-fold wider confidence limits (95% confidence limits: 0.06, 0.43).

109 bo within 48 h (hazard ratio [HR], 1.68; 95% confidence limit [95% CL], 1.19, 2.38) and 28 and 58 day

110 19 FFPE samples showed 100% sensitivity (95% confidence limit: 96.5-100%) and 100% specificity (95% c

111 limit: 96.5-100%) and 100% specificity (95% confidence limit: 99.3-100%) compared with reference ass

112 The upper confidence limit accounts for the skewed distribution of

113 s at least 93.5% by a conservative lower 95% confidence limit; after a definitely negative test resul

114 Results reported with 95% confidence limits and net reclassification improvement (

115 t the relationship is not linear, with large confidence limits, and EBCT may underestimate the total

116 e) the RR was 9.75 (P < 0.05, nonoverlapping confidence limits, AR = 123.9).

117 erent from one another when their respective confidence limits are estimated by jackknifing.

118 ge were defined as exceeding 95% test-retest confidence limits based upon the mean sensitivity using

119 at approximately 10 000 years ago (with wide confidence limits), but only limited subsequent migratio

120 5 square centimeters per gram (cm(2)/g) [68% confidence limit (CL)] (sigma(DM), self-interaction cros

121 ident rate ratio (IRR) = 0.98, p = 0.02, 95% Confidence Limits (CL) = 0.96-0.99).

122 Mean d(2,3)fs was 4.1 [95% confidence limits (CL) = 3.7, 4.5].

123 ession estimated hazard ratios (HRs) and 95% confidence limits (CL) for first-onset TMD.

124 cidence ratios (SIRs) with corresponding 95% confidence limits (CL) of HPV-associated subsequent mali

125 event after PCI (odds ratio [OR]: 4.33; 95% confidence limits (CL): 1.52 to 12.30), peak troponin T

126 e 1963 cohort (relative risk (RR) = 2.7, 95% confidence limits (CL): 1.6, 4.7) and the 1975 cohort (R

127 of graft loss (relative risk [RR] 0.90, 95% confidence limit [CL] 0.84-0.96, P<0.001), whereas TAC+A

128 us loads above 3.15 log(1)(0) copies/mL (95% confidence limit [CL] 2.73, 3.55) and paired rectal vira

129 disease (GVHD) for all patients was 57% (95% confidence limit [CL], 0.28, 0.86), and 73% (95% CL, 0.4

130 blacks (relative prevalence [RP], 0.75; 95% confidence limit [CL], 0.61 to 0.94) and Hispanics (RP,

131 ipate in any form of screening (OR, 2.3; 95% confidence limit [CL], 1.7, 3.1) and in colonoscopy scre

132 cing a rejection episode than DSEK eyes (95% confidence limit [CL], 2.0-111; P = 0.008) and 20 times

133 ival and event-free survival were 99% (lower confidence limit [CL], 97.4%) and 93% (lower CL, 88.6%),

134 oven influenza virus infection was 0.45 (95% confidence limit [CL]: -0.02, 0.69) for influenza B and

135 ng pregnancy (relative risk [RR] = 1.83; 95% confidence limit [CL]: 1.12, 3.00), lower respiratory il

136 ants (p = 0.011, odds ratio [OR] = 2.63, 95% confidence limits [CL] = 1.25-5.56; p = 0.026, OR = 2.38

137 ediction had an average error of 1.5 dB (95% confidence limits [CL], +/-3.7 dB).

138 progression (relative hazard [RH], 1.67; 95% confidence limits [CL], 1.20, 2.32; and RH, 1.45; CL, 1.

139 th PJS, the RR for all cancers was 15.2 (95% confidence limits [CL], 2, 19).

140 th an adjusted HR for mortality of 0.90 (95% confidence limits [CL]: 0.84 to 0.96), and an adjusted H

141 tral venous catheter (CVC) days [95% Poisson confidence limits (CLs): 2.12, 2.71 episodes/1000 CVC da

142 ntent-to-treat estimate was biased with poor confidence limit coverage, but the proposed estimate was

143 timate was largely unbiased with appropriate confidence limit coverage.

144 two sequential measurements below the lower confidence limit defined the endpoint for each parameter

145 (dB) is needed to be outside the normal 95% confidence limits, depending on the size of the stimulus

146 At 100% specificity, based on the 95% confidence limits derived from Group IV, OCT exhibited 1

147 samples from infected mice, with a mean (95% confidence limits) effect size of 4.2 (2.8-5.6), when di

148 method, incorporating pairwise deletion and confidence limits estimated from 1000 replicates using b

149 ard deviations of less than 1%, close to the confidence limit estimates.

150 The upper 95% confidence limit excluded the risk found for mumps menin

151 ace of this, equations are given for the 95% confidence limits expected for a Poisson process.

152 particular result in an SRF with a 95% upper confidence limit for ash content marginally below the 20

153 The upper 95% confidence limit for condomless anal sex was 0.71 per 10

154 or plus raltegravir group (p=0.07; lower 95% confidence limit for difference 10.2% vs specified non-i

155 rmation of the hypothesis that the lower 95% confidence limit for its sensitivity in detecting seriou

156 Therefore, the binomial upper 95% confidence limit for the failure rate of 0% is 7%.

157 Non-inferiority was defined as the upper 95% confidence limit for the hazard ratio (HR) for new WHO s

158 The 95% upper confidence limit for the mean 24-h QTc interval was 452

159 The upper confidence limit for the mortality difference was within

160 Efficacy was to be declared if the lower 90% confidence limit for the proportion of responders on QAX

161 The confidence limits for comparing the exposure using peak

162 ser's input clone sequences and analyses the confidence limits for each nucleotide position and for t

163 The confidence limits for g(s) fits derived using F statisti

164 The 95% confidence limits for individual MRI measurements were +

165 rooted macrophytes, with satisfactory narrow confidence limits for more than half of the estimated pa

166 The 90% confidence limits for periostin were 35.0 and 71.1 ng/mL

167 s can be addressed by plotting or tabulating confidence limits for points on a flexible curve fitted

168 utcome is common, and the problem of setting confidence limits for risk ratios.

169 Estimates and their confidence limits for simulated data sets confirm that t

170 The 95% confidence limits for the 4.7% increase in inappropriate

171 The confidence limits for the achieved in-plane hit rate and

172 The 95% confidence limits for the measurements were +/-0.53.

173 Confidence limits for these estimates are often wide, pa

174 on index is quite good, with the average 95% confidence limits for three measurements on each PCB bei

175 er of locations that were worse than the 95% confidence limits for total deviation (r = 0.51) and pat

176 was 32.0 +/- 6.1 ng/72 h (mean +/- SD at 95% confidence limit) for a donor population representing bo

177 the age- and race-adjusted ORs and ICRs (95% confidence limits) for heavy smoking (>or=41 pack-years)

178 clinical presentation, relative hazards (95% confidence limits) for MI or death were 2.0 (1.4 to 3.2)

179 operative mortality rate was 10+/-3% (+/-70% confidence limits) for patients receiving a CVG and 15+/

180 radiographic worsening in either cohort, and confidence limits in the analyses of vitamin D deficienc

181 o fMALDI-TOF/fHPLC was 0.797 +/- 0.0229 (99% confidence limit, n = 7) for a 30-mer peptide substrate

182 io fMALDI-TOF/fHPLC to 0.917 +/- 0.0184 (99% confidence limit, n = 7).

183 0 are forecasted to be 129,200 +/- 7742 (95% confidence limits) new patients, 651,330 +/- 15,874 long

184 A confidence limit of >99% was achieved for 36.2% of predi

185 patients was 0.05 (SD = 0.15), with an upper confidence limit of 0.30.

186 HIV transmission of zero, with an upper 95% confidence limit of 0.30/100 couple-years of follow-up.

187 ercept and methotrexate, since the 95% upper confidence limit of 0.41 for the difference in change in

188 of 1.12 or lower, as well as an upper 97.5% confidence limit of 1.33 or lower in the intention-to-tr

189 omprising 47% of the cohort) was 0.4% (upper confidence limit of 1.49%).

190 With an upper 95% confidence limit of 11.5% for the primary composite end

191 al dominant model, was 4%, with an upper 95% confidence limit of 31%.

192 be approximately 2.5%, with an upper 1-sided confidence limit of 4.4%.

193 total estimate is 393 Gg/yr with a 95% upper confidence limit of 854 Gg/yr (0.10% to 0.22% of the met

194 single dose of varenicline, with a 90% lower confidence limit of 89% occupancy for the thalamus and b

195 osition of the disc (MPD) fell below the 95% confidence limit of each eye's individual baseline range

196 op in either group (upper 95% exact binomial confidence limit of incidence for those who discontinued

197 le for certain power plants; and a lower 95% confidence limit of net calorific value (NCV) at 14.5 MJ

198 ived over 99,000 doses of Priorix (upper 95% confidence limit of risk: 1:27,000), in a regional datab

199 n of 1.6 million doses of Priorix (upper 95% confidence limit of risk: 1:437,000) in England and Wale

200 urvival at 3 years was 77% and the lower 95% confidence limit of this estimate of survival was 60%.

201 18 mL/min/g and 0.01 +/- 0.11 mL/min/g, with confidence limits of +/-0.36 and +/-0.22 mL/min/g for un

202 of retinal thickness measurements showed 98% confidence limits of +/-17 microm at fixation and +/-11

203 was 0.13 mm (95% CI, 0.03-0.22 mm), with 95% confidence limits of -0.54 and 0.80 mm.

204 0.03 mm (95% CI, -0.06 to 0.12 mm), with 95% confidence limits of -0.66 and 0.71 mm.

205 elta(34)S from -5.0 per thousand, within 95% confidence limits of -14.8 per thousand to 4.1 per thous

206 41% at 1 year, and 57% at 2 years, with 95% confidence limits of 10%, 28%; 30%, 55%; and 44%, 71%, r

207 ,000 scf methane (0.4-0.7 Mg) per event (95% confidence limits of 10,000-50,000 scf/event).

208 1.11 in UC and 0.75 in CD, with upper (95%) confidence limits of 2.41 and 1.37, respectively.

209 TDRS subfield was 264.5 (22.9) mum, with 95% confidence limits of 220.8 and 311.5 mum.

210 000 scf methane (0.02-0.2 Mg) per event (95% confidence limits of 500-12,000 scf/event).

211 90% confidence interval contained within the confidence limits of 80.00% and 125.00%.

212 or daily energy intake were determined using confidence limits of agreement for energy intake/estimat

213 y described regression equation, and the 95% confidence limits of agreement with measured mean LAP ex

214 JSW measurement was reproducible (95% confidence limits of agreement) to within +/-0.5 mm.

215 ampled by bootstrapping to determine the 95% confidence limits of each measurement's repeatability.

216 MTT values were derived from the statistical confidence limits of group I data and then applied to gr

217 stical testing with calculation of upper 95% confidence limits of the differences between active and

218 observed incidence rates fell within the 95% confidence limits of the model estimates.

219 attachment level change (from estimated 95% confidence limits of visit 1 data) ranged from 0.52 mm t

220 ed to be accurate within 0.95 +/- 0.58% (95% Confidence Limit) of a commercial potentiostat.

221 timate of hospitalwide incidence (mean+/-95% confidence limit) of sepsis syndrome was 2.0+/-0.16 case

222 d controls coupled with rigorous statistical confidence limits offer a new path toward investigating

223 nd itself easily to acceptable estimation of confidence limits on the estimated concentrations.

224 Because of the wide confidence limits on the mutation rates of these loci, t

225 was estimated to be 2.05 x 10(-5) (upper 95% confidence limit) or 4.75 x 10(-6) (50% confidence limit

226 49% versus 13.86%-19.59%, respectively, (95% confidence limit; P < 0.0001).

227 95% confidence limit) or 4.75 x 10(-6) (50% confidence limit) point mutations per nucleotide per yea

228 w are -0.50 +/- 0.54 and -0.79 +/- 0.65 (95% confidence limit) ppbv yr(-1), respectively, which corre

229 lack women living in these counties, and the confidence limit ratios indicated fairly consistent leve

230 /-2.4) kcal/mol was recovered using rigorous confidence limit testing.

231 effects estimates that provide more accurate confidence limits than the DL estimator.

232 .2 +/- 8.8% less DNA (N = 3 individuals, 93% confidence limit) than control cultures after 3 weeks of

233 As a remedy, this report proposes lower confidence limits that account for the multiple comparis

234 ons to compute numeric approximations of the confidence limits that do not require the use of any pro

235 ecause of the small number of cases and wide confidence limits, the data regarding amyotrophic latera

236 With 95% confidence limits, they should allow better discriminati

237 nd -19.7 to 16.7%, respectively, and the 95% confidence limits were -18.4 to 24.2% and -18.6 to +17.3

238 One-sided 95% lower confidence limits were 0.83 (RMDQ) and 0.97 (pain), demo

239 versus baseline periods across arms, but the confidence limits were broad, and the results should be

240 e compared by using a chi2 analysis, and 95% confidence limits were calculated.

241 diography correlated well (r = .93), and 95% confidence limits were determined.

242 s and SvO2 were compared, the ranges and 95% confidence limits were found to be clinically unacceptab

243 ne ED50 values (expressed as mg/kg, with 95% confidence limits) were: 10.2 (7.8-13.3), 1.4 (0.8-2.4)

244 hat will obtain the tightest reproducibility confidence limits, which, for a fixed total number of ex

245 h was found to be in good agreement at a 95% confidence limit with the certified value.

246 These wide range differences and confidence limits would lead to large errors if superior